Interface (NASDAQ:TILE) reported a stronger-than-expected start to fiscal 2026, with management pointing to broad-based sales gains, higher profitability and continued benefits from its One Interface strategy.
Chief Executive Officer Laurel Hurd said first-quarter net sales rose 7% year over year o
Treace Medical Concepts (NASDAQ:TMCI) reaffirmed its full-year 2026 revenue outlook after reporting a first-quarter revenue decline, as management said new product adoption is helping drive procedure volume momentum despite pricing and mix headwinds.
On the company’s first-quarter earnings call, Ch
Synaptics (NASDAQ:SYNA) reported its sixth consecutive quarter of double-digit year-over-year revenue growth in the third quarter of fiscal 2026, with management pointing to continued strength in core IoT products and expanding customer activity in Edge AI and robotics.
President and CEO Rahul Pate
Turtle Beach (NASDAQ:TBCH) reaffirmed its full-year 2026 outlook despite a weaker first quarter, as management pointed to channel inventory reductions, a challenging gaming accessories market and the timing of new product launches as key factors weighing on near-term results.
Chief Executive Office
Blackrock Tcp Capital (NASDAQ:TCPC) reported lower first-quarter adjusted net investment income and a decline in net asset value as the business development company continued to reposition its portfolio, reduce leverage and work through troubled credits.
On the company’s earnings call for the quart
Tucows (NASDAQ:TCX) reported higher first-quarter 2026 revenue and gross profit, but its losses widened as increased sales and marketing spending and legacy mobile obligations weighed on results, according to management commentary accompanying the company’s quarterly report.
Chief Executive Officer
Strattec Security (NASDAQ:STRT) reported lower third-quarter fiscal 2026 sales but improved gross margin and strong cash generation, as management said restructuring actions and operational changes continued to support profitability despite a softer automotive production environment.
President and
Starz Entertainment (NASDAQ:STRZ) executives said the company delivered a strong first quarter of fiscal 2026 and is moving faster than previously expected toward its long-term margin target, aided by content cost reductions, pricing discipline and a shift toward owned original programming.
Preside
Service Properties Trust (NASDAQ:SVC) reported first-quarter 2026 results that management said reflected progress on a broader repositioning plan, including significant debt reduction, continued hotel asset sales and a more measured approach to net lease acquisitions.
President and Chief Executive
Silvaco Group (NASDAQ:SVCO) reported first-quarter fiscal 2026 results that management said showed improving momentum across bookings, revenue, margins and cash, while the company guided for a return to non-GAAP operating profitability in the second quarter.
Chief Executive Officer and Director Wal
E.W. Scripps (NASDAQ:SSP) reported first-quarter 2026 results that management said reflected progress on a broad transformation plan, stronger local advertising tied to live sports and continued efforts to reduce debt through asset sales and portfolio actions.
Chief Financial Officer Jason Combs sa
Stratasys (NASDAQ:SSYS) reported lower first-quarter revenue and a wider GAAP loss as printer purchasing timelines remained extended, but management said recurring revenue, defense demand and growth at Stratasys Direct supported its outlook for the year.
On the company’s earnings call, Chief Execut
Stoke Therapeutics (NASDAQ:STOK) said its lead investigational therapy zorevunersen continued to show durable seizure reductions and improvements in measures of cognition and behavior in four-year open-label extension data, while the company remains on track to complete enrollment in its pivotal Pha
The Trump administration created an exemption allowing review of foreign-trained physicians with pending visa or green card applications, though approvals are not guaranteed.
Scholar Rock (NASDAQ:SRRK) said the U.S. Food and Drug Administration has accepted for review its resubmitted Biologics License Application for apitegromab, the company’s investigational treatment for children and adults with spinal muscular atrophy, and set a PDUFA action date of Sept. 30, 2026.
C
Sensus Healthcare (NASDAQ:SRTS) said its first quarter of 2026 marked a transition period as new dedicated CPT codes for superficial radiotherapy took effect, while revenue declined from the prior year due largely to the absence of sales to its historically largest customer.
Chairman and Chief Exec
